慢性阻塞性肺病(Chronic obstructive pulmonary disease，COPD) 是常見且容易導致死亡 的呼吸道疾病，吸入型支氣管擴張劑是治療COPD 患者主要藥物。近年來新型長效型乙二型 交感神經刺激劑和長效型抗膽鹼藥物陸續研發，臨床上也證實可有效改善COPD 症狀及肺功 能，且無明顯副作用，只要一天一次，更方便的給藥。因此目前在2017 年GOLD 指引，對 於穩定型COPD 患者，建議使用長效劑型支氣管擴張劑。

Chronic obstructive pulmonary disease (COPD) is the leading cause of morbidity and mortality in pulmonary diseases worldwide. Inhaled bronchodilators are the main therapeutic agents for COPD. Long-acting muscarinic antagonists and long-acting β2 sympathomimetic agonists have been developed in recent years. These agents have been proven to improve COPD symptoms and pulmonary functions. They have no significant adverse effects. The once-daily dosing is also more convenient for patients. Both agents are now recommended by the GOLD Strategy as a mainstay treatment for stable COPD patients.